Refoxy Pharmaceuticals筹集了910万欧元，用于推进其治疗特发性肺纤维化的新型FOXO3疗法-动脉网

Refoxy Pharmaceuticals raises €9.1 million to progress its novel FOXO3 therapeutics for Idiopathic Pulmonary Fibrosis

D-Pharm 等信源发布 2024-12-09 12:50



可切换为仅中文







Refoxy Pharmaceuticals GmbH is a preclinical biotech company developing small molecule activators of the FOXO3 transcription factor for the treatment of age-related diseases. The company announced a €9.1 million seed-extension financing led by Boehringer Ingelheim Venture Fund (BIVF), and joined by Apollo Heath Ventures, NRW.Venture, and High-Tech Gründerfonds (HTGF) to advance the development of novel therapeutic medicines in diverse indications, starting with idiopathic pulmonary fibrosis (IPF).

Refoxy Pharmaceuticals GmbH是一家临床前生物技术公司，开发FOXO3转录因子的小分子激活剂，用于治疗与年龄有关的疾病。该公司宣布了由勃林格殷格翰风险基金（BIVF）牵头、新南威尔士州阿波罗希思风险投资公司（Apollo Heath Ventures）加入的910万欧元种子延期融资。Venture和高科技Gründerfonds（HTGF）以促进多种适应症的新型治疗药物的开发，从特发性肺纤维化（IPF）开始。

IPF is a chronic, age-related interstitial lung disease with high mortality and limited treatment options that affects around three million people globally. It involves the buildup of scar tissue (fibrosis) in the lungs and progressively limits breathing capacity. Refoxy is taking a novel approach to tackle IPF’s complex biology by modulating a transcription factor that can orchestrate changes at multiple biological levels, with the potential to interfere with disease progression.

IPF是一种慢性，与年龄有关的间质性肺病，死亡率高，治疗选择有限，影响全球约300万人。它涉及肺部疤痕组织（纤维化）的积聚，并逐渐限制呼吸能力。Refoxy正在采取一种新方法，通过调节转录因子来解决IPF的复杂生物学问题，该转录因子可以在多个生物学水平上协调变化，并有可能干扰疾病进展。

'We are following biology. The evidence that FOXO3 activation can be therapeutically relevant continues to grow, not only in IPF but in multiple chronic disorders. This financing brings us one step closer to leveraging FOXO3 biology for novel therapeutics', Dr. Victor Bustos, co-founder and CEO of Refoxy.

“我们正在学习生物学。FOXO3激活可能与治疗相关的证据继续增加，不仅在IPF中，而且在多种慢性疾病中。Refoxy联合创始人兼首席执行官维克托·布斯托斯博士（Victor Bustos）表示，这笔资金使我们离利用FOXO3生物学进行新疗法又近了一步。

FOXO3 is one of the genes most robustly associated with a longer and healthier human lifespan. It helps tissues and organs fight diverse forms of stress, making it a compelling target for drug discovery. However, its complex biology has limited efforts to leverage its therapeutic potential. Dr. Victor Bustos, along with Prof.

FOXO3是与更长和更健康的人类寿命最密切相关的基因之一。它有助于组织和器官抵抗各种形式的压力，使其成为药物发现的引人注目的目标。然而，其复杂的生物学特性限制了利用其治疗潜力的努力。维克多·布斯托斯博士和教授。

Wolfgang Link, a world-renowned expert in FOXO3, co-founded Refoxy in partnership with Apollo Health Ventures. Their strategy focuses on identifying activators of FOXO3 through a proprietary drug discovery platform based on Prof. Link’s pioneering research called F.act finder (FOXO activator finder).

沃尔夫冈·林克是世界著名的FOXO3专家，与阿波罗健康风险投资公司合作成立了Refoxy。他们的战略重点是通过专有的药物发现平台来识别FOXO3的激活剂，该平台基于林克教授的开创性研究，称为F.act finder（FOXO activator finder）。

F.act finder has provided a lead series demonstrating the potential therapeutic benefit of FOXO3 modulation in IPF models, giving the company confidence in moving forward.

F、 act finder提供了一系列线索，证明了FOXO3调节在IPF模型中的潜在治疗益处，使公司对前进充满信心。

'We are thrilled to provide funding for Refoxy’s research on FOXO3 activation as a promising novel therapeutic approach. This perfectly aligns with our mission to support breakthrough developments and deliver innovative therapies to patients in need in the field of IPF', Dr. Niklas Czeloth, Investment Manager at BIVF and board member at Refoxy.

“我们很高兴为Refoxy关于FOXO3激活的研究提供资金，作为一种有前途的新型治疗方法。BIVF投资经理兼Refoxy董事会成员Niklas Czeloth博士表示，这完全符合我们支持IPF领域突破性发展并为有需要的患者提供创新疗法的使命。

In addition to BIVF, Refoxy’s board of directors is further strengthened by appointing Dr. Anela Vukoja from Apollo Health Ventures, Dr. Vera Mehler-de Graaff from NRW.Venture, and Dr. Christian Kannemeier as an observer from HTGF.

除BIVF外，通过任命阿波罗健康风险投资公司的Anela Vukoja博士和新南威尔士州的Vera Mehler de Graaff博士，Refoxy的董事会得到进一步加强。风险投资，以及Christian Kannemeier博士作为HTGF的观察员。

'As co-founding investors in Refoxy, we are excited about working together with the team and the strong syndicate of investors to advance its pipeline of FOXO3 enhancers in fibrosis and beyond. The company’s mission aligns with the increasing need for innovative therapies for all age-related disorders', Dr.

“作为Refoxy的共同创始投资者，我们很高兴与团队和强大的投资者财团合作，推进其在纤维化及其他领域的FOXO3增强剂管道。该公司的使命与日益增长的对所有与年龄有关的疾病的创新疗法的需求相一致。

Anela Vukoja, Principal at Apollo and Board Member of Refoxy.. .

阿波罗公司负责人、Refoxy董事会成员AnelaVukoja。

'In view of the innovative therapeutic approach being developed by Refoxy, our investment in the start-up is a good example of how promotional funding can foster innovative ideas ‘Made in NRW’', Johanna Antonie Tjaden-Schulte, member of the Managing Board of NRW.BANK.

NRW董事会成员Johanna Antonie Tjaden Schulte说：“鉴于Refoxy正在开发创新的治疗方法，我们对初创公司的投资是一个很好的例子，说明推广资金如何促进“NRW制造”的创新想法。银行。

'HTGF is proud to continue to invest in promising new drug targets and help bring this urgently needed treatment closer to IPF patients', Dr. Christian Kannemeier, Senior Investment Manager at HTGF.

HTGF高级投资经理克里斯蒂安·坎内梅尔博士说：“HTGF很自豪能够继续投资于有前途的新药靶点，并帮助将这种迫切需要的治疗方法更接近IPF患者。”。

https://www.bionity.com/en/news/1185079/refoxy-pharmaceuticals-raises-9-1-million-to-progress-its-novel-foxo3-therapeutics-for-idiopathic-pulmonary-fibrosis.html

Kizoo leads financing round in Reservoir Neuroscience to restore health to the aging brain

Kizoo领导水库神经科学融资回合，以恢复衰老大脑的健康

A first-in-kind compound reverses disease in blood vessels and repairs the damaged blood-brain barrier

第一种化合物可逆转血管疾病并修复受损的血脑屏障

Read news

阅读新闻